PT4161528T - Combinação de ruxolitinib com incb057643 para utilização no tratamento de neoplasias mieloproliferativas - Google Patents

Combinação de ruxolitinib com incb057643 para utilização no tratamento de neoplasias mieloproliferativas

Info

Publication number
PT4161528T
PT4161528T PT207812025T PT20781202T PT4161528T PT 4161528 T PT4161528 T PT 4161528T PT 207812025 T PT207812025 T PT 207812025T PT 20781202 T PT20781202 T PT 20781202T PT 4161528 T PT4161528 T PT 4161528T
Authority
PT
Portugal
Prior art keywords
incb057643
ruxolitinib
treatment
combination
myeloproliferative neoplasms
Prior art date
Application number
PT207812025T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PT4161528T publication Critical patent/PT4161528T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT207812025T 2020-06-03 2020-09-14 Combinação de ruxolitinib com incb057643 para utilização no tratamento de neoplasias mieloproliferativas PT4161528T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063034214P 2020-06-03 2020-06-03

Publications (1)

Publication Number Publication Date
PT4161528T true PT4161528T (pt) 2026-01-23

Family

ID=72659928

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207812025T PT4161528T (pt) 2020-06-03 2020-09-14 Combinação de ruxolitinib com incb057643 para utilização no tratamento de neoplasias mieloproliferativas

Country Status (23)

Country Link
EP (2) EP4161528B1 (cg-RX-API-DMAC10.html)
JP (2) JP7669396B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230031242A (cg-RX-API-DMAC10.html)
CN (1) CN115835868A (cg-RX-API-DMAC10.html)
AU (1) AU2020451061A1 (cg-RX-API-DMAC10.html)
CA (1) CA3184633A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003409A1 (cg-RX-API-DMAC10.html)
DK (1) DK4161528T3 (cg-RX-API-DMAC10.html)
ES (1) ES3058891T3 (cg-RX-API-DMAC10.html)
FI (1) FI4161528T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20251457T1 (cg-RX-API-DMAC10.html)
IL (1) IL298200A (cg-RX-API-DMAC10.html)
LT (1) LT4161528T (cg-RX-API-DMAC10.html)
MA (1) MA59868B1 (cg-RX-API-DMAC10.html)
MD (1) MD4161528T2 (cg-RX-API-DMAC10.html)
MX (1) MX2022015220A (cg-RX-API-DMAC10.html)
PH (1) PH12022553276A1 (cg-RX-API-DMAC10.html)
PL (1) PL4161528T3 (cg-RX-API-DMAC10.html)
PT (1) PT4161528T (cg-RX-API-DMAC10.html)
RS (1) RS67440B1 (cg-RX-API-DMAC10.html)
SI (1) SI4161528T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202600021T1 (cg-RX-API-DMAC10.html)
WO (1) WO2021247064A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi
EP4297750A1 (en) * 2021-02-25 2024-01-03 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
WO2024039883A2 (en) * 2022-08-19 2024-02-22 Translational Drug Development Llc Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms
WO2024144258A1 (ko) * 2022-12-28 2024-07-04 주식회사 삼양홀딩스 룩소리티닙의 다중 방출제어 정제 조성물 및 이의 제조 방법
EP4734995A1 (en) * 2023-06-28 2026-05-06 Board of Regents, The University of Texas System Quinoline carboxamides for use in the treatment of mpn

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
SMT202000133T1 (it) * 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi

Also Published As

Publication number Publication date
JP2025111539A (ja) 2025-07-30
IL298200A (en) 2023-01-01
MD4161528T2 (ro) 2026-03-31
PH12022553276A1 (en) 2024-02-19
DK4161528T3 (da) 2025-11-24
JP2023529365A (ja) 2023-07-10
CL2022003409A1 (es) 2023-05-26
FI4161528T3 (fi) 2025-12-12
AU2020451061A1 (en) 2022-12-15
KR20230031242A (ko) 2023-03-07
PL4161528T3 (pl) 2026-03-16
EP4161528A1 (en) 2023-04-12
RS67440B1 (sr) 2025-12-31
HRP20251457T1 (hr) 2026-01-02
SI4161528T1 (sl) 2026-01-30
WO2021247064A1 (en) 2021-12-09
MX2022015220A (es) 2023-03-08
CN115835868A (zh) 2023-03-21
EP4691563A3 (en) 2026-04-01
CA3184633A1 (en) 2021-12-09
ES3058891T3 (en) 2026-03-13
SMT202600021T1 (it) 2026-03-09
EP4691563A2 (en) 2026-02-11
JP7669396B2 (ja) 2025-04-28
LT4161528T (lt) 2026-02-10
EP4161528B1 (en) 2025-11-05
MA59868B1 (fr) 2025-11-28

Similar Documents

Publication Publication Date Title
IL285646A (en) Combined treatment includes mdm2 inhibitor and decitabine or cytrabine to treat AML
CA212757S (en) Meditation headset
IL276398A (en) Combined treatment for mastocytosis
SI4161528T1 (sl) Kombinacija ruksolitiniba z incb057643 za uporabo pri zdravljenju mieloproliferativnih neoplazem
CA212078S (en) Sunbed
CA196438S (en) Skin massager
IL264451B1 (en) A combination of abt-199 and achmetalstat for the treatment of aml
IL270752B (en) Pyrrolopyridine-aniline compounds for the treatment of skin disorders
PL3646876T3 (pl) Inhibitor telomerazy, imetelstat do leczenia zaburzeń mieloproliferacyjnych i nowotworów mieloproliferacyjnych
IL309238A (en) Treatment of symptoms associated with myeloproliferative tumors
MX393452B (es) Tratamiento de los trastornos depresivos.
ZA201807353B (en) 2¿anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
EP3621619C0 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF VISCERAL PAIN
LT3701051T (lt) Melatoniną palaikančių bakterijų pasirinkimas ir naudojimas kūdikių kolikoms mažinti
IL280663B1 (en) Thermochemical treatment of cellulosic materials
HK40091744A (en) Combination of ruxolitinib with incb057643 for use in the treatment of myeloproliferative neoplasms
IL267044A (en) Photodynamic therapeutic compounds and photodynamic treatment methods
HK40107739A (en) Treatment of symptoms associated with myeloproliferative neoplasms
PL4225291T3 (pl) Leczenie cholangiopatii za pomocą seladelparu
GB202118006D0 (en) Methods of treatment
GB202118007D0 (en) Methods of treatment
GB202106857D0 (en) Pyrrolobenzodiazepine phototherapy
GB202108245D0 (en) Methods of treatment
GB202007015D0 (en) Pyrrolobenzodiazepine phototherapy
GB202005874D0 (en) Methods of treatment